ALSAF Stock Overview
Safe Orthopaedics SA, a medical technology company, engages in the design, manufacturing, and marketing of sterile implants and single-use sterile surgical instruments for the treatment of spinal surgery.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Safe Orthopaedics SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.0006 |
| 52 Week High | €0.52 |
| 52 Week Low | €0.0004 |
| Beta | 0.87 |
| 1 Month Change | -25.00% |
| 3 Month Change | -85.00% |
| 1 Year Change | -99.88% |
| 3 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Shareholder Returns
| ALSAF | FR Medical Equipment | FR Market | |
|---|---|---|---|
| 7D | 0% | 1.6% | 1.2% |
| 1Y | -99.9% | 11.5% | 4.0% |
Return vs Industry: ALSAF underperformed the French Medical Equipment industry which returned 11.5% over the past year.
Return vs Market: ALSAF underperformed the French Market which returned 4% over the past year.
Price Volatility
| ALSAF volatility | |
|---|---|
| ALSAF Average Weekly Movement | 28.4% |
| Medical Equipment Industry Average Movement | 5.7% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.3% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: ALSAF's share price has been volatile over the past 3 months.
Volatility Over Time: ALSAF's weekly volatility has decreased from 38% to 28% over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 138 | Pierre Dumouchel | www.safeorthopaedics.com |
Safe Orthopaedics SA, a medical technology company, engages in the design, manufacturing, and marketing of sterile implants and single-use sterile surgical instruments for the treatment of spinal surgery. The company’s products portfolio includes SteriSpine PS, an all-round kit for the treatment of spinal fractures and degenerative pathologies, as well as essential kit for percutaneous treatment of spinal fractures; SteriSpine VA, a product platform for ready to use Kyphoplasty and Cement systems; SteriSpine LC, a ready to use instrumentation for lumbar cage portfolio, including Cedar and Elm; and SteriSpine CC, a ready to use instrumentation for cervical cage, such as Walnut. Safe Orthopaedics SA was founded in 2010 and is headquartered in Eragny-sur-Oise, France.
Safe Orthopaedics SA Fundamentals Summary
| ALSAF fundamental statistics | |
|---|---|
| Market cap | €6.72k |
| Earnings (TTM) | -€6.96m |
| Revenue (TTM) | €5.86m |
0.0x
P/S Ratio0.0x
P/E RatioIs ALSAF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALSAF income statement (TTM) | |
|---|---|
| Revenue | €5.86m |
| Cost of Revenue | €1.76m |
| Gross Profit | €4.11m |
| Other Expenses | €11.07m |
| Earnings | -€6.96m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | -0.62 |
| Gross Margin | 70.06% |
| Net Profit Margin | -118.84% |
| Debt/Equity Ratio | -609.1% |
How did ALSAF perform over the long term?
See historical performance and comparison